Remibrutinib in Sjogren's Syndrome Save
Dr. Michael Putman reports on abstract 1113 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.